Barry C Jones

Barry C Jones

UNVERIFIED PROFILE

Are you Barry C Jones?   Register this Author

Register author
Barry C Jones

Barry C Jones

Publications by authors named "Barry C Jones"

Are you Barry C Jones?   Register this Author

18Publications

363Reads

23Profile Views

Drug Metabolite Identification using UHPLC UV Spectroscopy and Parallelized Scans on a Tribrid Orbitrap Mass Spectrometer.

Rapid Commun Mass Spectrom 2020 Jan 22:e8735. Epub 2020 Jan 22.

Radiolabelled Chemistry & Metabolism, Pharmaron, Pegasus Way, Crown Business Park, Rushden, NN10 6ER, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/rcm.8735DOI Listing
January 2020

An Investigation into the Prediction of the Plasma Concentration-Time Profile and Its Interindividual Variability for a Range of Flavin-Containing Monooxygenase Substrates Using a Physiologically Based Pharmacokinetic Modeling Approach.

Drug Metab Dispos 2018 Sep 12;46(9):1259-1267. Epub 2018 Jun 12.

Departments of Modelling and Simulation, Oncology Drug Metabolism and Pharmacokinetics (V.P.R.), Departments of Drug Metabolism and Pharmacokinetics and Oncology (B.C.J., N.C., J.W.), and Department of Drug Safety and Metabolism (A.S.), IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom; and Pharmaron, Beijing, China (D.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.118.080648DOI Listing
September 2018

CYP-Mediated Sulfoximine Deimination of AZD6738.

Drug Metab Dispos 2017 11 23;45(11):1133-1138. Epub 2017 Aug 23.

Oncology IMED, AstraZeneca, Cambridge, United Kingdom (B.C.J., R.M., G.S.); and Oncology IMED, AstraZeneca, Waltham, Massachusetts (C.G.).

View Article

Download full-text PDF

Source
http://dmd.aspetjournals.org/lookup/doi/10.1124/dmd.117.0777
Publisher Site
http://dx.doi.org/10.1124/dmd.117.077776DOI Listing
November 2017

An Investigation into the Prediction of in Vivo Clearance for a Range of Flavin-containing Monooxygenase Substrates.

Drug Metab Dispos 2017 10 7;45(10):1060-1067. Epub 2017 Aug 7.

Oncology IMED, Astrazeneca, Cambridge, United Kingdom (B.C.J., N.C., J.W., V.P.R.), DSM Astrazeneca, Cambridge, United Kingdom (A.S.); DSM Astrazeneca, Gothenburg, Sweden (S.A.); and Pharmaron, Beijing, China (D.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.117.077396DOI Listing
October 2017

Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach.

Drug Metab Dispos 2017 01 24;45(1):35-41. Epub 2016 Oct 24.

Oncology Innovative Medicines and Early Development Biotech Unit (B.C.J.) and Drug Safety and Metabolism (H.R.), AstraZeneca, Cambridge, United Kingdom; Quantitative Clinical Pharmacology (S.J.), and Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit (K.P.K., T.B.A.), AstraZeneca, Mölndal, Sweden; Quantitative Clinical Pharmacology, AstraZeneca, Hertfordshire, United Kingdom (C.L.); Quantitative Clinical Pharmacology, AstraZeneca, Waltham, Massachusetts (K.V.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (T.B.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.116.072025DOI Listing
January 2017

Exploring concepts of in vitro time-dependent CYP inhibition assays.

Expert Opin Drug Metab Toxicol 2014 Feb 21;10(2):157-74. Epub 2013 Nov 21.

Corning Gentest Contract Research Services, Corning Life Sciences , 6 Henshaw Street, Woburn, MA 01801 , USA +1 781 935 5115. ext 2218 ; +1 781 938 8644 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425255.2014.856882DOI Listing
February 2014

Application of PBPK modelling in drug discovery and development at Pfizer.

Xenobiotica 2012 Jan 30;42(1):94-106. Epub 2011 Oct 30.

Pfizer Worldwide R&D, Department of Pharmacokinetics, Dynamics and Metabolism, Sandwich, Kent, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/00498254.2011.627477DOI Listing
January 2012

Cytochrome P450 metabolism and inhibition: analysis for drug discovery.

Prog Med Chem 2009 ;47:239-63

Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0079-6468(08)00206-3DOI Listing
June 2010

An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point.

J Pharm Biomed Anal 2008 Sep 17;48(1):92-9. Epub 2008 May 17.

Pfizer Global Research and Development, Pharmacokinetics Dynamic and Metabolism, Sandwich, Kent, UK CT13 9NJ, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpba.2008.05.011DOI Listing
September 2008

Induction of cytochrome P450: assessment in an immortalized human hepatocyte cell line (Fa2N4) using a novel higher throughput cocktail assay.

Drug Metab Dispos 2007 Feb 15;35(2):275-82. Epub 2006 Nov 15.

Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.106.012864DOI Listing
February 2007

CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.

Pharmacogenet Genomics 2006 Sep;16(9):637-45

Department of Clinical Toxicology, Central Laboratories & Blood Bank, King Fahad Medical City, Riyadh 11525, Kingdom of Saudi Arabia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.fpc.0000230411.89973.1bDOI Listing
September 2006

In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole.

Drug Metab Pharmacokinet 2003 ;18(5):287-95

Department of Pharmacokinetics Dynamics Metabolism, Nagoya Laboratories, Pfizer Inc., Taketoyo, Aichi, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2133/dmpk.18.287DOI Listing
March 2005

Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.

Drug Metab Dispos 2004 Nov 10;32(11):1201-8. Epub 2004 Aug 10.

Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.104.000794DOI Listing
November 2004

Reaction phenotyping in drug discovery: moving forward with confidence?

Curr Drug Metab 2003 Dec;4(6):527-34

Department of Pharmacokinetics, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389200033489235DOI Listing
December 2003

Predicting oral absorption and bioavailability.

Prog Med Chem 2003 ;41:1-59

Pfizer Global Research and Development, Sandwich Laboratories, PDM, Sandwich, Kent CT13 9NJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0079-6468(02)41001-6DOI Listing
June 2003

Structure-activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)- 5-[2-[(3-substituted)-1-azetidinyl]ethyl]-2-piperidones. 1. Selective antagonists of the neurokinin-2 receptor.

J Med Chem 2002 Nov;45(24):5365-77

Department of Discovery Chemistry, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm0209331DOI Listing
November 2002

Development of a combined protein and pharmacophore model for cytochrome P450 2C9.

J Med Chem 2002 May;45(10):1983-93

Department of Molecular Informatics, Structure & Design, Pfizer Global Research & Development, Sandwich Laboratories, Ramsgate Road, Sandwich, Kent CT13 9NJ, U.K.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm0110791DOI Listing
May 2002